Establishment Labs/$ESTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Establishment Labs
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in the designing, manufacturing, and marketing of silicone-filled breast and body-shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Ticker
$ESTA
Sector
Primary listing
Employees
1,056
Headquarters
Alajuela, Costa Rica
Website
ESTA Metrics
BasicAdvanced
$1.4B
-
-$3.08
0.85
-
Price and volume
Market cap
$1.4B
Beta
0.85
52-week high
$51.34
52-week low
$26.56
Average daily volume
324K
Financial strength
Current ratio
2.838
Quick ratio
1.545
Long term debt to equity
986.236
Total debt to equity
986.236
Interest coverage (TTM)
-2.72%
Profitability
EBITDA (TTM)
-54.028
Gross margin (TTM)
67.24%
Net profit margin (TTM)
-49.89%
Operating margin (TTM)
-35.43%
Effective tax rate (TTM)
-1.17%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
-12.78%
Return on equity (TTM)
-261.18%
Valuation
Price to revenue (TTM)
8.04
Price to book
63.11
Price to tangible book (TTM)
138.56
Price to free cash flow (TTM)
-17.758
Free cash flow yield (TTM)
-5.63%
Free cash flow per share (TTM)
-2.793
Growth
Revenue change (TTM)
17.22%
Earnings per share change (TTM)
-0.62%
3-year revenue growth (CAGR)
7.21%
3-year earnings per share growth (CAGR)
1.19%
What the Analysts think about ESTA
Analyst ratings (Buy, Hold, Sell) for Establishment Labs stock.
Bulls say / Bears say
U.S. Motiva sales momentum exceeded expectations, with Q2 2025 U.S. revenue of $10.3 million surpassing guidance, enabling the company to raise full-year revenue guidance to $208–212 million and signal strong market adoption (Investing.com).
Gross margin expansion to 68.8% in Q2 2025 (up from 65.6% a year ago) demonstrates improved pricing power and operational efficiencies, supporting stronger profitability trends as volumes scale (Investing.com).
The launch of Preservé™ in Brazil marks the expansion of the minimally invasive platform, positioning the company to capture new patient segments with advanced tissue-preserving techniques and drive future top-line growth (Medical Product Outsourcing).
Persistent operational losses continue to weigh on the company, with Q2 2025 loss from operations of $14.1 million and an adjusted EBITDA loss of $8.5 million despite revenue gains, highlighting the challenge of reaching profitability in 2025 (Investing.com).
Significant cash burn raises funding runway concerns: Q2 cash use of $14.5 million left a cash balance of $54.6 million and an additional $25 million available under the credit facility, implying the company may require refinancing or equity raises before achieving positive cash flow in 2026 (Investing.com).
SG&A expenses surged by $11.4 million in Q2 2025, driven by accelerated U.S. commercialization activities and marketing campaigns, putting further pressure on operating leverage and delaying breakeven (Investing.com).
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
ESTA Financial Performance
Revenues and expenses
ESTA Earnings Performance
Company profitability
ESTA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Establishment Labs stock?
Establishment Labs (ESTA) has a market cap of $1.4B as of October 24, 2025.
What is the P/E ratio for Establishment Labs stock?
The price to earnings (P/E) ratio for Establishment Labs (ESTA) stock is 0 as of October 24, 2025.
Does Establishment Labs stock pay dividends?
No, Establishment Labs (ESTA) stock does not pay dividends to its shareholders as of October 24, 2025.
When is the next Establishment Labs dividend payment date?
Establishment Labs (ESTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Establishment Labs?
Establishment Labs (ESTA) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.